Autres langues Cutia Therapeutics

Actions

2487

KYG2606C1006

Produits pharmaceutiques

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:41 31/07/2026			Varia. 5j.	Varia. 1 janv.
2,340 ^HKD	-2,50%		-2,90%	-48,46%

07/05	Cutia Therapeutics annonce l'autorisation de mise sur le marché de la crème topique locale à base de lidocaïne et de tétracaïne CU-30101	CI
07/05	Chine : feu vert réglementaire pour l'anesthésique local CU-30101 de Cutia Therapeutics	MT

Autres langues

07/05	Cutia Therapeutics Announces Drug Marketing Authorization for CU-30101 Localized Topical Lidocaine and Tetracaine Cream
07/05	Cutia Therapeutics' Topical Anesthetic CU-30101 Approved in China
07/05	Cutia Therapeutics says CU-30101 obtains drug marketing authorization by NMPA China
13/04	Cutia Therapeutics Completes Phase 3 Trial for Botulinum Toxin Product
13/04	Cutia Therapeutics says completion of phase III clinical trial of CU-20101
13/04	Cutia Therapeutics Announces Completion of Phase III Clinical Trial of CU-20101 Botulinum Toxin Type A for Injection for Improving Moderate to Severe Glabellar Lines in China
24/03	Cutia Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2025
24/03	Cutia Therapeutics' Loss Narrows in 2025 as Revenue Rises
16/03	Cutia Therapeutics says CU-40104 obtains clinical trial approval from NMPA, China
16/03	Cutia Therapeutics Receives Chinese Regulatory Approval to Begin Trials of Hair Loss Drug
16/03	Cutia Therapeutics Announces Clinical Trial Approval For Cu-40104 (Topical Dutasteride Agent) By the NMPA
19/01	Cutia Therapeutics Announces Cu-20101 for Improving Moderate to Severe Glabellar Lines Achieved Positive Topline Results from Phase III Clinical Trial in China
19/01	Cutia Therapeutics Says Phase 3 Trial of CU-20101 Meets Key Endpoints in China
30/12	Cutia Therapeutics Announces Board Changes, Effective December 30, 2025
19/11	China Accepts Cutia Therapeutics' ANDA Filing for New Topical Finasteride Spray
19/11	Cutia Therapeutics says abbreviated new drug application for CU-40105 accepted by NMPA China
18/11	Cutia Therapeutics Announces Abbreviated New Drug Application For CU-40105 (Self-Developed Topical Finasteride Spray)Accepted by the NMPA
10/11	Cutia Therapeutics' Acne Drug Data Selected for Oral Presentation at CDA Annual Meeting
10/11	Cutia Therapeutics Announces Post-Hoc Analysis of the Phase III Clinical Trial of CU-10201 (Topical 4% Minocycline Foam) in the People's Republic of China Accepted for Oral Presentation
30/09/25	Hairstetics Ltd. announced that it has received ?2 million in funding from Cutia Therapeutics
05/09/25	Cutia Therapeutics Raises Over HK$240 Million from Share Placement
29/08/25	Hong Kong Stocks End in Green Friday as Earnings Flurry Continues; Cutia Therapeutics Seeking HK$240.3 Million via Share Sale
29/08/25	Cutia Therapeutics Seeking HK$240.3 Million via Share Placement
29/08/25	Cutia Therapeutics announces placing of 28.9 million shares
28/08/25	Cutia Therapeutics Reports Earnings Results for the Half Year Ended June 30, 2025